Ponesimod Patent Expiration
Ponesimod is used for reducing circulating lymphocytes in treating relapsing forms of multiple sclerosis in adults. It was first introduced by Vanda Pharmaceuticals Inc
Ponesimod Patents
Given below is the list of patents protecting Ponesimod, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Ponvory | US11951097 | Methods of treating multiple sclerosis | Oct 10, 2042 | Vanda Pharms Inc |
| Ponvory | US10220023 | Dosing regimen for a selective S1P1 receptor agonist | Dec 10, 2035 | Vanda Pharms Inc |
| Ponvory | US12336980 | Dosing regimen for a selective S1P1 receptor agonist | Dec 10, 2035 | Vanda Pharms Inc |
| Ponvory | US9062014 | Crystalline forms of (R)-5-[3-chloro-4-(2,3-dihydroxy-propoxy)-benz[Z]ylidene]-2-([Z]-propylimino)-3-0-tolyl-thiazolidin-4-one | May 06, 2032 | Vanda Pharms Inc |
| Ponvory | USRE43728 | Thiazolidin-4-one derivatives | Nov 16, 2029 | Vanda Pharms Inc |
| Ponvory | US8273779 | Thiazolidin 4-one derivatives |
Dec 17, 2025
(Expired) | Vanda Pharms Inc |
| Ponvory | US9000018 | Thiazolidin-4-one-derivatives |
Nov 16, 2024
(Expired) | Vanda Pharms Inc |
Ponesimod's Family Patents
Explore Our Curated Drug Screens
Clinical Trials
Recent Clinical Trials on Ponesimod:
Sometimes companies keep conducting clinical trials even after the drug's approval to discover new formulations, methods of use, or new treatment indications, so they could file for additional patents or receive regulatory exclusivity extensions, such as pediatric exclusivity, potentially delaying generic competition. Based on these recent clinical trials, generic companies need to consider the potential for new intellectual property or regulatory hurdles. These strategic moves by the drug owner might delay generic substitution or lead to additional sales of the brand drug, even after patent expiry.
| Title | Lead Sponsor | Collaborators | Status | Phases |
|---|---|---|---|---|
 | ||||
| Open Label Study to Investigate the Safety and Efficacy of Ponesimod in Moderate-to-Severe Chronic Plaque Psoriasis | Vanda Pharmaceuticals | NA |
RECRUITING
(Sep 1, 2026)
| PHASE3 |
| Study to Evaluate the Efficacy and Safety of Ponesimod (VSP-128) in Patients With Moderately to Severely Active Ulcerative Colitis | Vanda Pharmaceuticals | NA |
RECRUITING
(Aug 1, 2026)
| PHASE3 |